A carregar...
Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics
AFN-1252, a potent enoyl-ACP reductase (FabI) inhibitor, is under development for the treatment of Staphylococcus aureus infections. The activity of AFN-1252 against two isolates of S. aureus, MSSA 26213 and MRSA S186, was studied in an in vitro pharmacodynamic model simulating AFN-1252 pharmacokine...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Maney Publishing
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3558987/ https://ncbi.nlm.nih.gov/pubmed/23433442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1179/1973947812Y.0000000060 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|